Vicki L Sato
CIK 1197020 · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VIR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PERKINELMER, INC. LEGAL DEPARTMENT
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALLO | Director | 162,575 | $1.22 | $198.3K | $0 | 6 | 2026-06-23 |
| VIR | Director | 1,078,391 | $10.45 | $11.26M | -$13.98M | 43 | 2026-05-04 |
| DNLI | Director | 107,976 | $18.63 | $2.01M | -$1.78M | 37 | 2025-01-03 |
| Akouos, Inc. (AKUS) Delisted | Director | — | $13.29 | — | $0 | 3 | 2022-12-02 |
| BMY | Director | — | $62.98 | — | $0 | 22 | 2021-02-03 |
| BWA | Director | 19,823 | $55.44 | $1.10M | $0 | 7 | 2020-05-01 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | — | $0.00 | — | $0 | 5 | 2019-06-12 |
| REVVITY, INC. (PKI) Delisted | Director | 29,970 | $115.24 | $3.45M | -$3.78M | 16 | 2017-02-10 |
| ALNY | Director | — | $225.88 | — | $0 | 4 | 2010-06-04 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 2 | 2008-05-23 |
Recent Filings · Page 3 of 17
162 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-08 | VIR | Notice (144) | −43,840 | -$345.9K | EDGAR |
| 2025-01-08 | VIR | Sell (S) | −10,960 | -$137.2K | EDGAR |
| 2025-01-03 | DNLI | Sell (S) | −3,080 | -$64.4K | EDGAR |
| 2025-01-02 | DNLI | Notice (144) | −6,160 | -$125.5K | EDGAR |
| 2024-11-12 | DNLI | Sell (S) | −1,020 | -$30.6K | EDGAR |
| 2024-11-05 | DNLI | Sell (S) | −3,080 | -$83.4K | EDGAR |
| 2024-09-16 | DNLI | Sell (S) | −1,020 | -$30.6K | EDGAR |
| 2024-09-13 | DNLI | Notice (144) | −6,160 | -$172.2K | EDGAR |
| 2024-09-04 | DNLI | Sell (S) | −3,080 | -$77.0K | EDGAR |
| 2024-07-03 | DNLI | Sell (S) | −3,080 | -$68.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.